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Abstract 
When challenged by viral DNA, the cytoplasmic DNA sensor cyclic GMP-AMP synthase 
(cGAS) signals through the adaptor protein stimulator of interferon genes (STING) to 
induce a primary type I IFN response. Studies from recent years have also revealed shared 
architecture between metabolism and innate immunity. Viruses have evolved to counteract 
these mechanisms. Human adenovirus (HAdV) early region 1A (E1A) protein antagonizes 
the cGAS-STING pathway to prevent an innate immune response by physically interacting 
with STING.  I hypothesize that the interaction between E1A and STING is mediated 
through several motifs and involves ribosomal protein S6 kinase beta-1 (S6K1). Using a 
series of co-immunoprecipitation assays, I determined that the interaction between STING 
and HAdV E1A is conserved and mediated through the E1A N-terminus region. I also 
found that E1A physically interacts with S6K1 and ribosomal protein S6 (RPS6). Further 
studies will reveal the biological function of these interactions.  
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Chapter 1 
1.1 Innate Immune Recognition of Pathogens and Trauma: 
PAMPs, MAMPs, and DAMPs 
Innate immunity is acknowledged as the first line of defense against invading foreign 
microbes and operates as a quick and sensitive counterattack mechanism. As response time 
post-exposure to an infectious agent can be absolutely paramount, sensors to detect 
incoming foreign microbial matter are strategically located within the cell. These sensors 
contain germline-encoded receptors called innate pattern recognition receptors (PRRs), and 
research over the past decade has shown that these PRRs have extensive breadth in host 
cell range and ligand specificity (Yoneyama et al., 2004; Kawai & Akira, 2011). Triggering 
of PRRs subsequently leads to intracellular signalling cascades that ultimately result in the 
transcriptional expression of inflammatory mediators that eliminate infected cells and 
pathogens (Takeuchi & Akira, 2010).  
Pathogen-associated molecular patterns (PAMPs) and microbe-associated molecular 
patterns (MAMPs) are conserved molecular structures found in microbial pathogens, such 
as flagellins, peptidoglycans, and lipopolysaccharides (Wu & Chen, 2014). However, 
nucleic acids can also act as PAMPs/MAMPs because DNA is an essential genetic material 
across all organisms (with the exception of RNA viruses). Nucleic acids themselves are 
not regarded as the ‘problem’, but rather the mislocalization of nucleic acids in the 
cytoplasm triggers specific PRRs, and detection of anomalous nucleic acids serves as a 
fundamental mechanism of host defense. Nucleic acids can also act as damage-associated 
molecular patterns (DAMPs), which are biomolecules derived from the host that trigger 
innate immunity in response to trauma, cellular stress, tissue damage, and necrotic cell 
death (Tang et al., 2013). 
However, there exists no perfect biological system, and the detection of DNA, particularly 
double-stranded DNA, by innate immune sensors can lead to autoimmune diseases such as 
Aicardi-Goutieres Syndrome (AGS) and Systemic Lupus Erythematosus (SLE)(Ablasser 
et al., 2013). Therefore, the host has evolved a range of distinct PRRs to identify different 
PAMPs and activate appropriate and specific cellular responses to combat infection 
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(Yoneyama et al., 2005; Ablasser et al., 2013). The innate immune sensors involved in 
sensing nucleic acids can be subdivided into multiple groups depending on where they are 
located within the cell, the cell type, and their targets of recognition (Kawai & Akira, 2011). 
To date, the Toll-like receptor (TLR) family is the most extensively studied of these groups 
and has provided new insights into the mechanisms by which PRRs operate.  
1.2    Toll-like Receptors 
Toll-like receptors are often cited as the prototypical PRRs that recognize PAMPs or 
damage-associated molecular patterns (DAMPs). These single transmembrane proteins 
contain leucine-rich domains designed to recognize PAMPs. Structurally, TLRs also 
contain a transmembrane domain, situated upstream of the cytosolic Toll/IL-1 receptor 
(TIR) domain, which is highly effective at transducing signals to the downstream adaptor 
proteins TIR-domain-containing adapter-inducing interferon-β (TRIF) and myeloid 
differentiation primary response gene 88 (MyD88)(Figure 1.1)(Bell et al., 2003; Bell et al., 
2005; Ishii et al., 2005; Kawai & Akira, 2010).  TLRs undergo dimerization, which is 
initiated by the binding of extracellular ligands. This triggers the interaction of the TIR 
domain with adapter molecules to initiate downstream signaling. The adaptor proteins 
TRIF and MyD88 both activate nuclear factor-ĸB (NF-ĸB), but the MyD88 pathway results 
in the activation of interferon regulatory factor 7 (IRF7), while the TRIF pathway leads to 
the activation of interferon regulatory factor 3 (IRF3)(Xu et al., 2000; Tao et al., 2002 
Khan et al., 2004; Kawai & Akira, 2010). These IRFs are integral members of the 
interferon regulatory factor family of transcription factors. Activated IRF3 and IRF7 
translocate to the nucleus and play a role in transcriptional activation of type I interferon 
(IFN) genes. IRF3 induces interferon-beta (IFN-β) expression, while IRF7 induces IFN-β 
and interferon-alpha (IFN-α) expression to activate innate immune cell responses 
(Colonna, 2007). The type I IFN response is described in detail in section 1.6.  
 
The genetic family of TLRs has expanded relatively quickly over the last decade. To date, 
five (of ten) TLRs in humans have been characterized for their ability to recognize nucleic 
acids, and these include: TLR3, TLR4, TLR7, TLR8 and TLR9 (O’Neill et al., 2013; Tao 
et al., 2016). Several groups took it upon themselves to identify the ligand specificities of  
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Figure 1.1 Signaling pathways of the toll-like receptors (TLRs)s, RIG-like 
receptors (RLRs), and DNA sensors. Diagram depicting a general outline of the three 
most studied PRRs and their signaling pathways. TLRs are found within endosomal 
compartments and anchored to the cell surface membrane. TLRs activate the 
downstream adaptor proteins MyD88 or TRIF, which recruit downstream molecules to 
trigger the secretion of pro-inflammatory cytokines and type I IFN. RLRs RIG-1 and 
MDA5 activate and recruit the adaptor protein MAVS to trigger NF-κB and type I IFN. 
The cytoplasmic DNA sensor cGAS binds DNA and triggers the formation of a second 
messenger (cGAMP) (not shown) to activate STING, which in turn traffics from the ER 
and recruits TBK1 and IRF3, leading to the secretion of type I IFN. Dashed arrow 
represents signaling between STING and RIG-1 (Wu et al., 2017). Adapted from Ma & 
Damania, 2016. 
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nucleic acid-sensing TLRs.  Both synthetically generated ligands together with pathogen-
derived nucleic acids, such as genetic viral fragments, were used to challenge TLRs.  For 
example, TLR3 was determined to be a double-stranded RNA (dsRNA) sensor using the 
synthetic analog polyinosinic-polycytidylic acid (Marshall-Clarke et al., 2007), and then 
subsequently shown to restrict several RNA viruses, including West Nile Virus, and 
Respiratory Syncytial Virus (Negishi et al., 2008; Wu & Chen, 2014). It was also 
discovered that TLR3 could recognize a select number of dsRNA replicative intermediates 
from various single-stranded (ssRNA) viruses (Bell et al., 2006).  
  
With the exception of TLR3 and TLR4, many TLRs are expressed on the cell surface. 
TLR3 and 4 are located within the endoplasmic reticulum, endosomes, and endolysosome. 
TLR7 recognizes ssRNA sequences rich in guanosine and uridine, and thus operates to 
restrict Influenza A Virus, Vesicular Stomatitis Virus (VSV) and Sendai Virus. 
Additionally, TLR7 and the functionally similar TLR8 have gained attention for their 
recognition of Human Immunodeficiency Virus (HIV) (Diebold et al., 2004; Heil et al., 
2004; Hofmann et al., 2016).   
The notable discovery of the first DNA sensor TLR9 was made in the year 2000 by Hemmi 
and colleagues. TLR9 is located within the endosomal lumen and monitors for microbial 
unmethylated cytosine-phosphate-guanine (CpG) dinucleotides (Krieg, 2004). Monitoring 
for unmethylated CpG DNA allows for the vital distinction between host and foreign DNA, 
as host genomes generally have methylated cytosines at CpG sites. Up to 90% of the 
vertebrate genomic CpGs are believed to be in a methylated state (Kass et al., 1997; Ng & 
Bird, 1999; Hoelzer et al., 2008). The evolutionary pressures placed upon host cells from 
microbes drives innate immunity into a diversification of the levels of nucleic acid-sensing 
TLRs. Many of the TLRs are structured such that their ligand binding domains face inwards 
toward the endosomal lumen of immune cells. This effectively prevents them from 
detecting any incoming pathogens traveling through the cytoplasm.  The role of TLRs, or 
lack thereof, in innate immunity was questioned with the observation that several different 
nonimmune cells, such as fibroblasts, do not have TLRs yet are capable of mounting innate 
immune responses to infection (O’Neill et al., 2013).  This led to the subsequent discovery 
of pathways involved in cytoplasmic nucleic acid sensing (Wu & Chen, 2014).  
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1.3    Cytoplasmic Sensing of Nucleic Acids 
As a foreward to the topic of cytoplasmic sensing of nucleic acids, it should be mentioned 
that pre-2017, researchers categorized cytoplasmic sensing pathways into two main 
families, each characterized by their mode of ligand recognition; DNA or RNA. However, 
new research is beginning to reveal signaling events between cytoplasmic sensors and 
downstream adaptor proteins across these families, thus categorizing whole pathways 
under groups of strictly DNA-detecting or RNA-detecting would appear too general. 
Therefore, the following summary of cytoplasmic sensing pathways should be viewed, 
keeping in mind, that some studies will be reanalyzed to accommodate these new insights. 
 
Viral RNA (vRNA) is a very strong TLR-independent activator of type I IFNs (Diebold et 
al., 2003) and detection within the cytoplasm of vRNA occurs through RIG-1-like 
receptors (RLRs)(Yoneyma et al., 2004). The first RLR to be described was the 
cytoplasmic sensor retinoic acid-inducible gene 1 (RIG-1), which was required for dsRNA-
induced IFN induction. The second most notable RLR is the cytoplasmic RNA sensor 
melanoma differentiation associated gene 5 (MDA5) (Figure 1.1)(Yoneyama et al., 2005; 
Kolakofsky et al., 2012). Sensors that constitute an RLR have a highly conserved domain 
structure; a DExD/H-box helicase core composed of two helicase domains. The C-terminal 
domain of RLRs is the area where ligand specificity has evolved (Kolakofsky et al., 2012; 
Luo et al., 2013). MDA5 and RIG-1 also have two caspase activation and recruitment 
domains (CARDs), which mediate the downstream signaling to adaptor protein 
mitochondrial antiviral-signaling pathway (MAVS)(Figure 1.1)(Jiang et al., 2012; 
Kowalinski et al., 2011). The ligand specificities between RIG-1 and MDA5 are dissimilar, 
with the length of the RNA being the critical distinction factor. MDA5 recognizes long 
synthetic RNA fragments (>3.9Kb), while RIG-I is activated by shorter synthetic RNA 
fragments (∼300bp) (Kato et al., 2008). The structure of the RNA cap is also used by RIG-
1 as a method of detecting vRNA. Pathogenic RNA carries a 5’-triphosphate (5’ppp) group 
(Hornung et al., 2006; Pichlmair et al., 2006) while eukaryotic mRNA evades RIG-1 
detection because of post-translational modifications that result in 5’-end capping with 7-
methyl guanosine (m7G0) and 2’-O-methylation of 5’-end nucleotides (Devarkar et al., 
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2016). RNA derived from viruses can either be recognized by MDA5 or RIG-1, or both. 
Detection of RNA by MDA5 sensors is less understood compared to RIG-1, but one study 
demonstrated that high molecular weight RNA can form web-like structures because of an 
inclusion of both ssRNA and dsRNA, and this induces IFN activity in a MDA5-dependent 
manner (Pichlmair et al., 2009). Looking further downstream at the adaptor protein MAVS, 
Sun and colleagues (2006) demonstrated through mouse knockout studies that viral 
induction of type I IFN was abolished in MAVS -/- mice, leaving the mice highly 
susceptible to lethal Vesicular Stomatitis Virus infection. The induction of type I IFNs and 
cytokines by MDA5/RLRs and MAVS also acts through two cytosolic kinases, IκB kinase 
(IKK) and tank-binding kinase 1 (TBK1), which activate IRF3 and IRF7 via 
phosphorylation (Seth et al., 2005). 
Intriguingly, Ishii and colleagues (2006) discovered that B-form double-stranded DNA 
poly(dA:dT) could activate type I IFNs in a RIG-I/MAVS dependent manner in certain cell 
types. There was much confusion over this phenomenon, but that was subsequently 
diminished when two independent studies were conducted demonstrating that poly(dA:dT) 
could be converted to RNA that bore a 5’triphosphate group and had double-stranded 
secondary structures, much like the ligands for RIG-1. DNA-dependent RNA Polymerase 
III (Pol-III) was the enzyme responsible for synthesizing 5’triphosphate RNA from the 
poly(dA:dT) template (Ablasser et al., 2009; Chiu et al., 2009). The plasticity of Pol-III 
acting as a DNA sensor allows the RIG-1/MAVS pathway to defend against pathogens by 
an alternative mechanism. However, the strict dependence that Pol-III has for AT-rich 
sequence, and the fact that Type I IFN production could occur through sequence-
independent mechanisms hinted that another DNA-sensing pathway was yet to be found 
(Wu & Chen, 2014).  
1.4    The cGAS-STING Pathway 
In 1908, Mechnikov spoke of the immunostimulatory abilities of nucleic acids, long before 
the structure of DNA was established in 1953 (Mechnikov, 1908). The main cytosolic DNA 
sensor that could lead to such a robust type I IFN response remained elusive until 2012, 
when the breakthrough by Dr. Zhijian Chen’s group led to the identification of cyclic GMP-
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AMP synthase (cGAS) using quantitative mass spectrometry and biochemical fractionation 
(Sun et al., 2013). cGAS is a nucleotidyl transferase (NTase) and as such, possesses the 
structurally conserved NTase core domain. cGAS provides surveillance within the 
cytoplasm and upon recognizing and binding target sequence-independent DNA, cGAS 
catalyzes the synthesis of the cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP) from 
ATP and GTP (Sun et al., 2013; Wu et al., 2013). Extensive work by multiple groups went 
into describing the phosphodiester linkages between GMP and AMP, predominantly to 
show that a mix of phosphodiester products could be produced. Both an endogenous 
mammalian form and bacterial form of cGAMP have been structurally analyzed. The 
metazoan 2’3’-cGAMP and bacterial second messengers c-di-GMP, c-di-AMP, and 3’3’-
cGAMP can all bind and activate the adaptor molecule stimulator of interferon genes 
(STING), triggering innate immune defense (Gao et al., 2013). The secretory mechanisms 
of these CDNs continues to be studied (Civril et al., 2013; Zhang et al., 2013; Ablasser et 
al., 2013; Diner et al., 2013).  
STING (also known as MITA, MPYS, ERIS and TMEM173) was discovered between 
2008 and 2009 by four independent groups through the use of cDNA expression library 
screens (Jin et al., 2008; Zhong et al., 2008; Ishikawa et al., 2009; Sun et al., 2009). STING 
is a direct sensor of CDNs and has a broad tissue distribution (Zhong et al., 2008). STING 
is anchored to the endoplasmic reticulum through its N-terminal domain, and is comprised 
of four transmembrane domains (Ishikawa et al., 2008). The use of crystallography has 
also revealed that the carboxyl-terminal domain of STING extends into the cytosol. The 
native, unliganded state of STING is a symmetrical dimer in which two monomers of the 
C-terminal domain form a cleft. This cleft is the binding site of cGAMP, and each STING 
dimer can bind one cGAMP (Shang et al., 2012; Ouyang et al., 2012). Dimerized STING 
binds cGAMP (Figure 1.2) which triggers relocalization of STING from the ER to the 
Golgi complex (Ishikawa et al., 2009; Shang et al., 2012). STING is phosphorylated by 
TBK1 at Serine 366, while the carboxyl-terminal region of STING activates TBK1, which 
in turn stimulates the phosphorylation of IRF3 (Tanaka & Chen, 2012). STING is often 
described as a ‘scaffold protein’ because of its interaction with both TBK1 and IRF3 to 
promote phosphorylation of IRF3. The study by Tanaka and Chen (2012) demonstrated 
that selective mutations in STING that disrupted its binding to IRF3 abolished  
	 9	
  
Figure 1.2 Structure of human STING in complex with c-di-GMP. (A) Schematic 
representation of human STING where black and yellow boxes represent the 
transmembrane domain and cytoplasmic C-terminal domain, respectively. Disordered 
regions are represented with dashed lines. (B) Ribbon diagram of STING C-terminal 
domain in complex with c-di-GMP. Monomer A is yellow and monomer B is purple. 
The c-di-GMP is in stick representation. Taken from Shang et al., 2016. Image 
reproduced with permission of the rights holder, Nature. 
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phosphorylation of IRF3 without impacting activation of TBK1. Phosphorylated IRF3 
translocates to the nucleus to induce the transcription of IFN genes (Figure 1.3). Signal 
transducer and activator of transcription 6 (STAT6) has also been similarly identified as 
being recruited by STING for subsequent phosphorylation by TBK1 and translocation to 
the nucleus. This leads to the induction of genes responsible for immune cell homing, 
namely expression of the STAT6-dependant chemokines CCL2, CCL20, and CCL26 
(Chen et al., 2011). 
 
Optimal signaling of STING can enhance the antiviral response, but chronic activation of 
STING leads to an excessive and harmful type I IFN and pro-inflammatory cytokine 
response. Therefore, STING undergoes several different post-translational modifications 
for optimal signaling, including ubiquitination, phosphorylation, sumoylation and 
proteasome-mediated degradation. The ubiquitin ligase tripartite motif-containing protein 
56 (TRIM56) was demonstrated to bind STING and mediate ubiquitination of STING at 
lysine 150, which can facilitate STING dimerization and binding to TBK1 (Tsuchida et al., 
2010). The TRIM32 ubiquitin ligase was also shown to interact with STING and is 
important for STING-TBKI interaction upon Sendai Virus and Herpes Simplex Virus 1 
infection (HSV-1) (Zhang et al., 2012). STING can also be negatively regulated through 
several mechanisms. Recently, a study by Hu and colleagues (2016) revealed how STING 
can be stabilized by sumoylation and the SUMO protease SENP2 can mediate degradation 
of STING after desumoylation. Ubiquitin ligase ring finger protein 5 (RNF5)-mediated 
lysine 48-linked ubiquitination can also control degradation of STING (Zhong et al., 2009). 
Within human diploid cells, a negative feedback system has been put in place to avoid 
excessive STING response whereby RIG-1 and IL-6 promote STING degradation by 
activating/dephosphorylating UNC-51-like kinase (ULK1). Interestingly, this negative 
feedback mechanism is not present in HEK293 cells (Wu et al., 2017).   
 
1.5    Viral Evasion of the cGAS-STING Pathway 
 
The Red Queen Hypothesis (L.M. Van Valen, 1973) proposes that organisms must 
constantly evolve to survive against evolving opposing organisms. Viruses have adapted 
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Figure 1.3 The cGAS-STING DNA sensing pathway. The DNA sensor cGAS binds 
DNA and catalyzes the formation of the second messenger 2’3’- cGAMP. 2’3’- cGAMP 
binds to the ER bound adaptor protein STING and activates IKK and TBK1. STING 
and IRF3 are phosphorylated by TBK1 to form a STING-TBK1-IRF3 complex. 
Phosphorylated IRF3 dimerizes and enters the nucleus, where it functions with NF-kB 
to induce the expression of type I IFN and pro-inflammatory cytokines (Adapted from 
Chen et al., 2016). 
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many different methods of evading detection within the cytoplasm through antagonizing 
the cGAS-STING DNA sensing pathway. Being the first DNA virus reported to activate 
STING in vivo and in vitro, human HSV-1 is widely used in experimental systems as a 
viral activator of the cGAS-STING pathway. In one study, knockout of STING in mice 
resulted in lethal susceptibility to HSV-1 infection (Kalamvoki & Roizman, 2014). 
However, it should be noted that Kalamvoki & Roizman (2014) reported that STING, while 
critical for cellular restriction of HSV-1, could also be necessary for HSV-1 replication in 
certain cell types. 
 
Continuing with the Herpes Viral family, Kaposi’s Sarcoma-Associated Herpesvirus 
(KSHV) can also activate the cGAS-STING pathway. The KSHV viral interferon 
regulatory factor 1 (vIRF1) inhibits cGAS-STING dependent IFN-β induction by 
preventing STING from binding TBK1, disallowing phosphorylation of STING (Ma et al., 
2015). ORF52, an abundant KSHV tegument protein, was also shown to directly inhibit 
cGAS enzymatic activity through a mechanism involving both cGAS binding and DNA 
binding. A conserved mechanism is likely at play as the ORF52 homologs in related 
Herpesviruses also demonstrate this inhibitory effect (Wu et al., 2015). Finally, the N-
terminally truncated cytoplasmic isoforms of KSHV latency associated nuclear antigen 
(LANA) can antagonize the cGAS-STING sensing pathway through direct binding with 
cGAS, effectively allowing reactivation of latent KSHV (Zhang et al., 2016).  
 
Within the family Hepadnaviridae, Hepatitis B Virus polymerase inhibits STING-triggered 
IFN-β promoter activation and can bind STING to attenuate lysine 63-linked 
polyubiquitination and functional activation, without modulating STING protein levels. 
The RNase H domain is believed to be the interacting partner that effectively suppresses 
STING (Liu et al., 2015). 
 
Initial studies involving human Adenovirus by Falck-Pedersen’s group (2014) concluded 
that the cGAS/STING pathway was vital for type I IFN induction in response to 
Adenovirus. In addition, they did not find evidence of suppression of cGAS/STING-
dependent TBK1/IRF3 activation, at least up to 6 hours post-infection. However, these 
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experiments were undertaken with recombinant Adenoviruses that omitted the Adenoviral 
early genes (i.e. E1A) that regulate antiviral strategies. Lau and colleagues (2015) 
investigated previous observations that most immortalized and tumor cell lines (e.g. 
HEK293, HeLa, HEK293T) fail to respond to intracellular DNA, whereas primary cell 
lines mount a vigorous DNA-activated antiviral response through activation of type I IFN. 
Their study tested for type I IFN presence in HEK293 and HeLa cells after transfection 
with DNA. Compared to primary human fibroblasts, HEK293 and HeLa cells did not 
mount robust responses to transfected DNA. An understanding of how these cells were 
immortalized by viral oncogenes (HEK293 cells with the human Adenovirus type 5 E1A 
oncogene, and HeLa cells derived from a cervical tumor and positive for HPV18) led to 
the hypothesis that a common Leu-X-Cys-X-Glu protein motif sequence present within 
E1A and HPV18 E7 may be the point of interaction with STING. Other studies looking at 
Adenovirus and IFN production include one by Look and colleagues in 1998, which 
reported that E1A blocked STAT1 activation after IFN-β was produced (Look et al., 1998; 
Ma & Damania, 2017). Collectively, these studies on Adenovirus suggest that upstream 
cGAS/STING-dependent signaling may not affect Adenoviral replication while E1A is 
expressed, but further study is required.  
The question of whether STING is sufficient to act as a direct sensor for DNA has been 
debated within the literature. While the C-terminal domain of STING can independently 
associate with dsDNA, it occurs at a significantly lower binding affinity to that of cGAS 
(Kd of 200 µM vs. Kd of 88 nM)(Abe et al., 2013). Zhang and colleagues (2014) 
demonstrated that adding STING back into HEK293T cells, which do not express 
endogenous STING or cGAS, could restore an IFN-β response to cyclic di-nucleotides. 
However, this IFN-β response could not be restored upon challenge with dsDNA. As 
mentioned earlier, HEK293 cells are also unable to produce a type I IFN response when 
challenged with DNA, despite the presence of endogenous STING. When Lau and 
colleagues (2015) put cGAMP (5 µM) into HEK293 cells to stimulate STING, they could 
not induce a type I IFN response. However, when Zhang and colleagues (2014) put 
cGAMP into HEK293 cells to stimulate STING, they reported an almost 30-fold increase 
in IFN-β mRNA response. They also reported a very low increase in endogenous IFN-β 
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expression in response to immunostimulatory DNA. This puts forward the question of 
whether STING expression alone, can stimulate a biologically relevant IFN-β response in 
HEK293 cells.  
1.6    Type I IFN Signaling 
The secretion of type I IFNs is a pivotal antiviral mechanism found in almost all cells that 
operates to restrict viral growth and spread. The type I IFN family encodes multiple IFN-
α gene products and a single IFN-β gene. Generally, type I IFN responses are divided into 
two mechanisms, a primary response where the host cell can activate IFN gene expression, 
and a secondary response whereby IFN from the primary response binds to type I IFN 
(IFNARs) receptors on neighboring cells, leading to the activation and expression of 
hundreds of interferon stimulatory genes (ISGs) that ultimately promote further production 
of IFN- β and IFN-α (McNab et al,. 2015).  
 
Cells that express TLRs or have intracellular nucleic acid sensing pathways can initiate the 
primary type I IFN response. Through TLR signaling, TLRs engage with the adaptor 
proteins previously mentioned, TRIF and MyD88, which recruit the kinases TBK1 and 
IKK for IRF3 activation and translocation to the nucleus for transcription of IFN- β or –α 
genes. Some TLR-adaptor protein complexes recruit the IL-1R-associated kinases (IRAKs) 
and TNF receptor-associated factors (TRAFS) to interact with IKKα and activate IRF7 
(Liu et al., 2015).  
Both the adaptor proteins STING and MAVS have a conserved C-terminal pLxIS (p- 
hydrophilic residue, S- phosphorylation site) motif. The phosphorylation of this site occurs 
at the time of ligand binding and a mutation within this motif abolishes recruitment of 
IRF3. After STING and MAVS are activated by the adaptor proteins TBK1 and TBK1/IKK 
respectively, a conserved positively-charged patch on the IRF3 molecule binds STING and 
MAVS. This triggers recruitment of a second IRF3 molecule, which upon phosphorylation, 
binds with the first monomer to form a dimer. The activated IRF3 dimer translocates to the 
nucleus to induce expression of IFN- β or –α (Liu et al., 2015; Lau et al., 2015; McNab et 
al. 2015). 
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1.7    Metabolism and Immune Regulators   
The intricate relationship between metabolism and immune regulators is gradually being 
elucidated. This is generating much interest, as the innate immune regulation of metabolic 
pathways remains poorly understood because the systemic inflammation seen in chronic 
diseases can often overshadow direct underlying molecular causes. Recently, Hasan et al. 
(2016) established TBK1-mTORC1 (mechanistic target of rapamycin complex 1) as a key 
regulatory axis between cell-intrinsic immune signaling and metabolism. mTORC1 is one 
of two distinct complexes formed by the interaction of several proteins with mTOR. mTOR 
is a serine/threonine protein kinase and a member of the phosphoionsitide 3-kinase (PI3K)-
related kinase family. The mTORC1 pathway controls major processes such as autophagy 
and lipid and protein synthesis by responding to inputs from cellular cues such as stress, 
growth factors, amino acids, and oxygen (Laplante & Sabatini, 2012). Hasan et al. (2016) 
put forward the concept that chronic TBK1-STING activation and trafficking can lead not 
only to the recruitment of TBK1 and IRF3 signaling, but also bring TBK1 within close 
proximity to mTORC1 on the lysosomes. TBK1 was found to suppress mTORC1, leading 
to the dysregulation of cellular metabolism.  
Wang et al. (2016) later demonstrated that the mTORC1 substrate S6K is recruited to the 
STING-TBK1-IRF3 complex to promote IFN signaling during DNA stimulation. The two 
forms of ribosomal protein S6 kinase (S6K), S6K1 and S6K2, are effector serine-threonine 
kinases downstream of mTOR (Wang et al., 2016). To characterize the profile of 
adenovirus-induced IRF3 phosphorylation in mouse bone marrow– derived dendritic cells 
(BMDCs), they transduced wild-type BMDCs with recombinant human adenovirus 
serotype 5 (rHAdV-5) vector carrying deletions of E1 and E3, which are involved in 
mediating adenovirus replication and host immunomodulation. They determined that 
S6Ks, especially S6K1, were required for rHAdV-induced activation of IRF3. The 
phosphorylation of IRF3 was profoundly impaired in S6K1-/-S6K2-/- BMDCs. 
Immunoblotting analysis showed that recombinant rHAdV promoted translocation of IRF3 
to the nucleus in wild-type BMDCs but not in S6K1-/- S6K2-/- BMDCs. As previously 
discussed, STING has a scaffold function and binds both TBK1 and IRF3, but the binding 
of IRF3 to STING was abolished in S6K1-/- S6K2-/- BMDCs. Finally, through a series of 
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co-immunoprecipitation experiments, Wang and colleagues demonstrated that S6K binds 
STING to promote IRF3 phosphorylation.  
1.8     Human Adenoviruses 
The work in this thesis investigates the interplay between human Adenovirus and the 
STING pathway.  As such, I will briefly introduce human Adenoviruses, which are well 
characterized genera in the Adenovirus family of DNA viruses.  Infection by Adenoviruses 
affects human populations worldwide. While many infections present as asymptomatic, 
these viruses are able to infect multiple organ systems, generally causing mild self-limiting 
illnesses including gastroenteritis, conjunctivitis, and pharyngitis. However, for children 
and immunocompromised individuals, infection can lead to more serious complications 
(Krilov, 2005; Walls et al., 2003). 
The type and severity of disease can also be dependent on the infectious Adenoviral 
species, with Adenovirus F and G generally causing gastroenteritis, whereas Adenovirus 
D can cause conjunctivitis (Table.1.1) (Chang et al., 2008; Sambursky et al., 2007; Walls 
et al., 2003). A select number of Adenoviruses can be linked with specific historical 
outbreaks. For example, Adenovirus 14 is considered responsible for a fatal pneumonia 
outbreak in the United States of America in 2005 (Lewis et al., 2009). 
Adenoviruses are used to study cell cycle control, DNA replication, transcription mRNA 
processing, apoptosis and immunological responses. Identified in 1953, they are small non-
enveloped viruses with a linear double-stranded DNA genome of approximately 35 kbp. 
There are 100 members within the Adenovirus family, which infect a wide range of species 
covering reptiles, avian, and mammals. There are currently 57 members of human 
Adenovirus, which are separated into 7 species categorized A through G and characterized 
by their biological properties (Table 1.1)(Jones et al., 2007; Walsh et al., 2011). They are 
labelled as oncogenic viruses, but do not actually cause cancer in humans (Mackey et al., 
1976; Green et al., 1980). In 1962, human Adenovirus 12 was found to cause tumours in 
baby hamsters, which was the first example of a human virus inducing cancers. However, 
not all Adenoviruses cause tumours in rodents, but within tissue culture, they can transform 
rodent cells. The differences in tumourgenicity can be traced to immune response strategies 
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(Trentin et al., 1962; Gallimore, 1972).  
Human Adenovirus 5 (HAdV-5) interacts with the host coxsackie-adenovirus receptor 
(CAR)(Bewley et al., 1999). The virions enter the cell through receptor-mediated 
endocytosis, and are released into the cytoplasm via acidification of the endosome 
(Wickham et al., 1993). The genome undergoes uncoating and travels to the nucleus via 
the cellular microtubule network. Upon reaching the nucleus, the first gene transcribed is 
the early region 1A gene (E1A).  E1A performs many functions in the infected cell, 
including the rapid induction of transcription of the other early genes: E1B, E2, E3 and E4 
(Fessler & Young, 1998; Tollefson et al., 2007).  In addition to its role as a potent viral 
transactivator, the E1A protein abolishes the activity of the retinoblastoma protein (pRB) 
and its family members p107 and p130, which repress the E2F family of transcription 
factors. Cell cycle control and progression from the G1 to S phase is largely controlled by 
the E2F family (Berk, 1986; DeCaprio, 2009). Abolishing the control of E2F through the 
interaction of E1A with pRB promotes cell cycle progression, a well known trait of E1A 
function. It is hypothesized that the activation of cell cycle progression in the infected cell 
increases the availability of substrates for efficient viral progeny production (Pelka et al., 
2008).  E1A also functions to modulate innate immunity, which is described in detail in 
section 1.9. 
1.9    E1A as a Molecular Hub Protein 
The E1A oncoprotein is a classic example of an intrinsically disordered protein that can 
operate as a molecular hub (Pelka et al., 2008). E1A displays nuclear and 
nucleocytoplasmic localization and can interact with a large number of different cellular 
proteins to regulate a wide range of biological processes, including the transcription of viral 
and cellular genes, cell cycle, apoptosis, differentiation, transformation, and immune 
responses (Figure 1.4). E1A is differentially spliced to produce five isoforms, which have 
mRNA sedimentation rates of 13S, 12S, 11S, 10S, and 9S. The two largest of these 
products are 13S and 12S, which encode proteins of 289 and 243 amino acids in length, 
respectively (Perricaudet et al., 1979; Stephens & Harlow, 1987). Comparing the largest 
sequences of E1A proteins across species identifies four highly conserved regions, referred 
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Table 1.1 Biological properties of the seven human adenovirus species. Human 
Adenovirus species A through G, their hemagglutination group, serotypes, tumorigenicity 
in animals, transformation is tissue culture, sequence GC percentage, and linked clinical 
infection/disease. Adapted from Berk (2007), Ghebremedhin (2014), and Jones et al., 
(2007). 
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Figure 1.4 E1A is a molecular hub protein. Graphic demonstrating the primary and 
secondary interactors of E1A. Modeled with the Gephi 0.9.1 software with data from 
BioGRID build 3.4.144. E1A is shown as the center molecule, with the primary 
interactors represented in the larger coloured circles. Relative sizes are correlated with 
number of binding partners. The secondary interactors are represented by the smaller 
coloured circles. This diagram represents 31 primary interactors and 2125 unique 
secondary interactors. Created by and reproduced with permission from Dr. Joe 
Mymryk (Western University, unpublished, 2017). 
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to as CR1, CR2, CR3 and CR4 (Figure 1.5). These would indicate regions that are essential 
for adenoviral E1A function (Avvakumov et al., 2002). The N-terminus of E1A of most 
adenovirus types is predicted to form an α-helix, while the CR regions 1, 2 and 4 are 
intrinsically disordered. This allows E1A to form numerous interactions with cellular 
proteins through short linear interaction motifs (SLIMs). E1A mediates its effects on 
cellular processes through protein-protein interactions, as E1A does not directly bind DNA 
and has no enzymatic activity (Ferguson et al., 1985). SLIMs can be 3 to 10 residues is 
length and are typically found within intrinsically disordered regions of a protein, but also 
can be found on surfaces of solvent-exposed alpha helices. Interactions that are of low 
affinity or transient, are mediated by SLIMs, so stable binding between some protein-
protein interactions requires multiple SLIMs mediating the interaction (Davey et al., 2001; 
Pelka et al., 2013; Van Roey et al., 2014). There exist a number of HAdV-5 E1A SLIMs 
found in the CR2 region, within close proximity to each other (Figure 1.6). The LxCxE 
motif within CR2 is used to interact with pRB, in addition to being recently proposed to 
interact with STING (Dyson et al., 1992; Fattaey et al., 1993; Lau et al., 2015). The 
neighboring PxLxP and EVIDLT motifs are used to interact with BS69 and small ubiquitin-
like moiety (SUMO) conjugase ubiquitin conjugase 9 (UBC9), respectively (Ansieau & 
Leutz, 2002; Avvakumov et al., 2004; Lau et al., 2015; Yousef et al., 2010). The potential 
ability of E1A to interact with multiple partners suggests that, in addition to its ability to 
sequester or re-localize individual targets, it may perform a “scaffold” like function to bring 
various targets into virally-mediated protein complexes not present in uninfected cells. 
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Figure 1.6 Small linear motifs within conserved region 2 of HAdV-5. Amino acid 
residues 108-139 of HAdV-5 E1A. The PXLXP, EVIDLT and LXCXE motifs are 
highlighted with their reported binding partners BS69, UBC9, and pRB. 
 
HAdV-5      GPVSMPNLVPEVIDLTCHEAGFPPSDDEDEEG
108 139
SUMO 
conjugase
UBC9
pRb
Cell cycle 
control (G1 to S 
phase)
BS69
Interacts with 
tri-methylated 
histone H3.3 
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1.10 E1A and Innate Immune evasion 
With respect to immune evasion strategies, the first indication that E1A could block IFN 
signaling was in 1988 when Reich and colleagues used E1A-deletion mutagenesis 
experiments to demonstrate that E1A blocks interferon signaling in infected HeLa cells. 
This was followed up with mapping studies that indicated the N-terminus was responsible 
for modulating transcriptional activation of IFN target genes (Kalvakolanu et al., 1991; 
Anderson and Fennie, 1987). In 2012, Fonseca and colleagues showed how E1A disrupts 
the transcription of intereferon stimulatory genes (ISGs) by antagonizing chromatin 
remodeling complexes. How E1A antagonizes the primary type I IFN response is less well 
understood. As mentioned previously, Lau and colleagues (2015) proposed that E1A can 
antagonize the STING pathway. A detailed mechanism of this antagonism has not been 
elucidated and many questions regarding the consequences of this interaction remain. 
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1.11    Rationale, Hypothesis, and Objectives 
 
Since the discovery of the cytoplasmic DNA sensor cGAS in 2012, extensive research has 
been undertaken to elucidate how the cGAS-STING pathway limits viral replication. In 
equal measure, the vast array of evasion strategies employed by viruses to prevent a 
primary interferon response has also been studied. The ability of a virus to escape innate 
immune detection is paramount to its survival. HAdV-5 E1A was identified as an 
antagonist of the cGAS-STING DNA sensing pathway by the group of Stetson in 2015 
(Lau et al., 2015). They proposed that a small linear LXCXE motif encoded by HAdV-5 
E1A could mediate an interaction with STING in the cytoplasm. However, the nature of 
this protein-protein interaction is poorly understood and its conservation across Adenoviral 
species is unknown. This LXCXE motif was previously identified for its role in mediating 
the interaction between E1A and pRb in the nucleus. The potential for this motif to have 
dual function requires further investigation and multiple motifs are likely required for 
stable binding between E1A and STING.  Therefore, and I set out to characterize the 
interaction between E1A and STING. 
 
In 2016, the group of Lichty (Wang et al., 2016) identified S6K1 as an additional binding 
partner of the STING-TBK1-IRF3 complex. S6K1 is a mTORC1 substrate and their study 
supports work by Hasan et al. (2016) that established a TBK1-mTORC1 regulatory axis 
between cell intrinsic immunity and metabolism. The suppression of mTORC1 activity by 
TBK1 during chronic STING activation, and the known interaction between S6K1 and 
STING led me to question if E1A targets S6K1 function.  The nature of the relationship 
between E1A and S6K1 is currently unknown. Therefore, I set out to determine if E1A 
interacts with S6K1, and potentially the S6K1-STING-TBK1-IRF3 complex.  
 
Based on the rationale, I hypothesize that antagonism of the STING-pathway by adenovirus 
E1A requires the LXCXE motif, in conjunction with additional E1A motifs that also 
mediate binding with S6K1. To test my hypothesis, I have formed two objectives: 
 
1. Characterize the interaction between E1A and STING and determine the 
conservation of this interaction in different human Adenoviral species. 
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2. Determine if E1A interacts with S6K1 in complex with STING.  
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Chapter 2 
2       Materials and Methods  
2.1    Cell Culture 
Human Embryonic Kidney 293 (HEK293) cells, HT1080 human fibrosarcoma cells, IMR-
90 primary human lung fibroblast cells, and A549 human alveolar basal epithelia cells were 
all derived from frozen laboratory stocks and cultured in Dulbecco’s Modified Eagle’s 
Medium (Multicell) supplemented with 10% calf serum (Gibco) and 1% PenStrep 
(100U/ml Penicillin and 100µg/mL Streptomycin, Multicell). Cells were cultured at 37°C 
with 5% CO2.  
2.2   Plasmids 
HAdV E1A plasmids were prepared and constructed by myself, and other (past and 
present) members of the laboratory (Table 2.1)( * indicates plasmids I modified, sub-
cloned, or constructed myself). E1A mutants were generated by PCR-based mutagenesis 
or sub-cloned into the appropriate vectors. E1A mutants were either tagged with GFP or 
contained no tag and cloned into pcDNA3.1 vectors. The human STING open reading 
frame was synthesized by Integrated DNA Technologies (gBlocks Gene Fragments) and 
generated with a C-terminal haemagglutinin (HA) epitope tag. The STING-HA fragment 
was subsequently cloned into a pcDNA3.1 vector. The mouse S6K1-HA plasmid was 
kindly gifted from Brian Lichty (McMaster University). S6K2 and RPS6 open reading 
frames were synthesized by ThermoFisher (GeneArt Cloning Service) and cloned into 
pcDNA3.1 vectors.  
Transformation of all plasmids were conducted using competent DH5α E.coli grown in 
Luria Broth (LB) supplemented with ampicillin (50µg/ml, BioShop) or kanamycin 
(20µg/ml, Bioshop). Large scale plasmid purification was conducted using the PureLink 
HiPure Plasmid Midiprep kit (Invitrogen). 
 
	 31	
Table 2.1 List of plasmids used in this study. 
# Name Parent Vector Characteristics 
1 GFP-13S Ad3  pGFP Full length 13S E1A of Ad3 
2 GFP-13S Ad4 pGFP Full length 13S E1A of Ad4 
3 GFP-13S Ad5 pGFP Full length 13S E1A of Ad5 
4 GFP-13S Ad9 pGFP Full length 13S E1A of Ad9 
5 GFP-13S Ad12 pGFP Full length 13S E1A of Ad12 
6 GFP-13S Ad40 pGFP Full length 13S E1A of Ad40 
7 GFP-13S Ad52 pGFP Full length 13S E1A of Ad52 
8 GFP-12S pGFP 12S E1A of Ad5 
9 GFP-11S pGFP 11S E1A of Ad5 
10 GFP-10S *     pGFP 10S E1A of Ad5 
11 GFP-N-terminus * pGFP AA 1-80 of Ad5 E1A 
12 GFP-CR2 pGFP AA 93-139 of Ad5 E1A 
13 GFP-CR3 * pGFP AA 139-204 of Ad5 E1A 
14 GFP-C-terminus * pGFP AA 187-289 of Ad5 E1A 
15 GFP- N-terminus pGFP AA 1-14 of Ad5 E1A 
16 GFP- N-terminus pGFP AA 14-22 of Ad5 E1A 
17 GFP- N-terminus pGFP AA 16-22 of Ad5 E1A 
18 GFP- N-terminus pGFP AA 29-49 of Ad5 E1A 
19 GFP-N-terminus (∆4-25) * pGFP Plasmid #11 with ∆4-25 
20 GFP-N-terminus (∆26-35)  pGFP Plasmid #11 with ∆26-35 
21 GFP-N-terminus (∆30-49) pGFP Plasmid #11 with  ∆30-49 
22 GFP-∆N-terminus * pGFP Plasmid #3 with ∆1-80 
23 GFP-dl1105 pGFP Plasmid #3 with ∆70-81 
24 GFP-dl1106 pGFP Plasmid #3 with ∆90-105 
25 GFP-dl1107 pGFP Plasmid #3 with ∆111-123 
26 GFP-dl1108 pGFP Plasmid #3 with ∆124-127 
27 GFP-dl1109 pGFP Plasmid #3 with ∆128-138 
28 13S Ad5 * pcDNA3.1 Full length 13S E1A of Ad5 
29 dl1106 pcDNA3.1 Plasmid #28 with ∆90-105 
30 dl1107 * pcDNA3.1 Plasmid #28 with ∆111-123 
31 dl1108 * pcDNA3.1 Plasmid #28 with ∆30-49 
32 GFP- Ad3 N-terminus pGFP AA 1-14 of Ad3 
33 GFP- Ad5 N-terminus pGFP AA 1-14 of Ad5 
34 GFP- Ad9 N-terminus pGFP AA 1-14 of Ad9 
35 GFP- Ad12 N-terminus pGFP AA 1-14 of Ad12 
36 GFP- Ad40 N-terminus pGFP AA 1-14 of Ad40 
37 GFP- Ad52 N-terminus pGFP AA 1-14 of Ad52 
38 Human HA-STING * pcDNA3.1 Full length STING 
39 Mouse HA-S6K1 pcDNA3.1 Full length mS6K1 
40 S6K2 * pcDNA3.1 Full length S6K2 
41 RPS6 * pcDNA3.1 Full length RPS6 
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2.3   Plasmid Transfections  
All transfections and co-immunoprecipitation assays were conducted in 10cm dishes 
(Sarstedt). HT1080 cells were seeded at 2 x 106 cells prior to transfection the following 
day with 5 µg of STING-HA expression constructs, 5 µg of full length E1A-GFP, 5 µg of 
E1A deletion mutants (Table 2.1), 5 µg of mouse S6K1-HA, 5 µg of human S6K2, 5 µg of 
human RPS6, 5 µg GFP, or 5 µg pcDNA3. 
Transfections were conducted using X-tremeGene HP DNA Transfection Reagent (Roche, 
6366244001) according to the manufacturer’s protocol. HEK293 cells were seeded at 2.5 
x 106 cells prior to transfection the following day with 5 µg STING-HA, 5 µg full length 
E1A, 5 µg E1A deletion mutants, or 5 µg E1A-GFP.The pRb-GFP plasmid was used as a 
positive technical control, the 13S-GFP and 13S-pcDNA3.1 plasmids were used as positive 
controls, and the GFP and pcDNA3.1 plasmids were used as negative controls.  
2.4   Co-Immunoprecipitation 
Cells were harvested 24 hr post-transfection and pelleted by centrifugation at 500 RCF for 
3 minutes at 4°C. The cells were then washed with phosphate buffered saline (PBS) 
(4.2mM Na2HPO4, 2.7mM KCl, 173mM NaCl, and 1.5mM KH2PO4 (BioShop)). Cellular 
pellets were lysed at 4°C with 0.8mL NP-40 lysis buffer (0.5% NP-40, 150mM NaCl, and 
50mM Tris-HCl, pH 7.8 (BioShop) supplemented with 0.6% Mammalian Tissue Protease 
Inhibitor Cocktail (Sigma). The lysate was then centrifuged and 2% of the supernatant was 
aliquoted for sample input control. Sepharose-Protein A beads were transferred to the cell 
lysate in addition to either anti-HA antibody, anti-GFP antibody, anti-STING antibody, 
anti-E1A (M73 and M58) antibody, or anti-RPS6 antibody (Table 2.2). The samples were 
then rotated at 4°C for either 4 hr or overnight. Samples were then washed 3 to 5 times 
with NP-40 lysis buffer. The samples were then re-suspended in LDS sample buffer (2X, 
NuPage; Thermo Fisher) and 0.2M DTT (BioShop) before being denatured at 98°C for 10 
min.  
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Table 2.2 List of antibodies used in this study. 
Specificity Description Usage Company Catalogue # 
 
GFP 
Rabbit 
polyclonal 
 
Primary 
 
Clontech 
632592 
 
HA 
Rat 
monoclonal 
 
Primary/IP 
 
Roche 
11867423001 
 
E1A (M58) 
Epitope: 1-
120 AA 
 
Mouse 
monoclonal 
 
 
Primary/IP 
 
In house 
hybridoma 
 
N/A 
 
E1A (M73) 
Epitope: 271-
289 AA 
 
Mouse 
monoclonal 
 
 
Primary/IP 
 
In house 
hybridoma 
 
 
N/A 
STING 
D2P2F 
Rabbit 
monoclonal 
 
Primary/IP 
 
Cell Signaling 
 
13647  
 
S6K 
Rabbit 
polyclonal 
 
Primary/IP 
 
Cell Signaling 
 
2708 
RPS6 
5G10 
Rabbit 
monoclonal 
 
Primary/IP 
 
Cell Signaling 
 
2217 
 
Actin 
Rabbit 
polyclonal 
 
Primary 
 
Sigma 
M-7023 
 
Rat IgG 
 
Goat 
 
Secondary 
 
Thermo 
Scientific 
31470 
 
Rabbit IgG 
 
Goat 
 
Secondary 
 
Santa Cruz 
Sc-2004 
 
Mouse IgG 
 
Rabbit 
 
Secondary 
 
Santa Cruz 
Sc-358923 
 
HA  
12CA5 
 
Mouse 
monoclonal 
 
IP 
 
In house 
hybridoma 
N/A 
 
Note: Antibodies used for immunoprecipitations were added directly to the cell lysate. 
Primary and secondary antibodies are diluted in 5% w/v Skim Milk with TBS-T or 3% 
BSA with TBS-T.  
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2.5   Western Blotting Analysis 
Samples were prepared and loaded into NuPAGE 10% or 4-12% Bis-Tris polyacrylamide 
gels (Invitrogen). Resolution by electrophoresis was at 200V with MES running buffer 
(50mM MES, 50mM Tris, 3.47mM SDS, and 1.03mM EDTA (BioShop)) and samples 
were transferred to polyvinylidene fluoride (PVDF) membrane (Amersham Hybond, GE 
Healthcare Life Science) with trasnfer buffer (25mM Bicine, 25mM Bis-Tris, 1.03mM 
EDTA, 20nM Chlorobutanol, and 10% Methanol (BioBasic)). The membrane was blocked 
for 1hr at room temperature with 5% w/v Skim Milk Powder (BioShop) in TBS-T (20mM 
Tris, 136mM NaCl (BioShop)), and 0.1% Tween-20 (Sigma). Primary antibodies (Table 
2.2) were diluted in either 5% w/v Skim Milk in TBS-T, or 3% Bovine Serum Albumin 
(Sigma) in TBS-T. Membranes were washed with TBS-T before appropriately diluted 
secondary antibodies (Table 2.2) were applied for 1hr at room temperature. Luminanta 
Crescendo Western horseradish peroxidase (HRP) Substrate or Forte Cresendo Western 
HRP Substrate (Millipore) were used to detect protein according to the manufacturer’s 
protocol. Images were developed on the Amersham Hyperfilm Enhanced 
Chemiluminescence (ECL) membrane (GE Healthcare) with the Konica Minolta SRX-
101A automated film processor according to the manufacturer’s protocol.  
2.6   Statistical Analysis 
Each co-immunoprecipitation experiment was replicated either two or three times. 
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Chapter 3 
3.1  Mapping the Interaction Between HAdV-5 E1A and 
STING 
Identifying and defining the regions of HAdV E1A that mediate interaction with STING 
can provide insight into the nature of this protein-protein interaction. Lau et al. (2015) 
suggested that the E1A LXCXE motif is necessary and sufficient for this interaction, but by 
drawing comparisons to the functional importance of the E1A LXCXE-mediated 
interaction with pRb, the possibility of a multi-region interaction cannot be dismissed. The 
LXCXE motif can be found in several viral and cellular proteins, with several of the latter 
showing mixed capacity and transient binding for pRb. Structural analysis of LXCXE 
motifs from multiple proteins revealed the importance of the side chain residues in making 
strong hydrophobic interactions with the target domains. Structural analysis has shown that 
the highly positive surface of the pRb domain LXCXE binding cleft repels the positive 
residues in the LXCXE motif and flanking residues (Singh et al., 2005). Therefore, analysis 
of the interaction between E1A and STING should be extended beyond the 5 amino acid 
residue LXCXE motif. 
3.1.1 HAdV-5 E1A Major Isoforms Bind STING 
Differential splicing of E1A produces multiple isoforms of varying length, which form at 
certain stages of infection. The 5 major isoforms (Figure 3.1A) have mRNA sedimentation 
rates of 13S, 12S, 11S, 10S, and 9S and consist of 289 residues (R), 243R, 217R, 171R, 
and 55R respectively (Figure 3.1A). The 13S and 12S major isoforms are expressed in the 
early phases of infection, while the 11S, 10S, and 9s follow later in infection (Perricaudet 
et al., 1979; Stephens & Harlow, 1987). Analyzing the interaction between STING and the 
E1A isoforms allows for a general mapping of the interaction, revealing key deductions. 
For example, the 12S isoform does not contain the CR3 region. Four isoforms of E1A, 
namely 13S, 12S, 11S and 10S were prepared in GFP-tagged constructs for co-transfection 
with the HA-tagged STING construct. HT1080 cells were co-transfected with HA-tagged  
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AAA   9S  (55R)
LXCXE
Figure 3.1. STING binds the four largest isoforms of HAdV-5 E1A. (A) Diagram 
depicting the structure of E1A mRNA transcripts. Boxes represent the coding regions, 
which are all read in the same frame, with the exception of 9S (Figure adapted with 
permission from Dr. Joe Mymryk, Western University, unpublished data) (B) HT1080 
cells were transfected with 5 µg human STING-HA expression vector and 5 µg of either 
13S-GFP, 12S-GFP, 11S-GFP, or 10S-GFP E1A expression vector. After 24 hr, cells 
were harvested and lysed, followed by immunoprecipitation of HA and western blotting 
for GFP-tagged E1A proteins. GFP was used as a control and pRb-HA was used as a 
technical positive. IgG HC denotes the heavy chain. IgG LC denotes the light chain. 
Inputs shown in the bottom panel. Results representative of three independent 
experiments. 
A	
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STING and GFP-tagged 13S, 12S, 11S, 10S, E1A from HAdV-5. A plasmid encoding HA 
tagged pRb was used as a technical positive control for interaction with E1A.	
	
Our laboratory has previously demonstrated that an E1A CR2 construct possessing the 
LXCXE motif forms a strong interaction with pRb in co-immunoprecipitation experiments 
(unpublished data). After 24 hr, cells were harvested and lysed, followed by 
immunoprecipitation of HA. Western blotting using anti-GFP polyclonal antibody 
demonstrated that all four HAdV-5 E1A isoforms tested could interact with STING in vitro 
(Figure 3.1B). All four isoforms contain the LXCXE motif, so this result is within 
agreement with the prediction made by Lau and colleagues (2015). However, these E1A 
isoforms also share common regions within the N-terminus and CR4 region. 
3.1.2  HAdV-5 E1A N-terminus Region Binds STING 
To better map the region of interaction on HAdV-5 E1A, I performed a series of co-
immunoprecipitation experiments using mutants encompassing the conserved regions of 
HAdV-5 E1A (Figure 3.2A). HT1080 cells were co-transfected with STING-HA and the 
following GFP-tagged 13S E1A mutants: 1-82 AA, which contains the N-terminal region 
and CR1 residues (42-72AA); 93-139AA which spans CR2 (116-139); 187-289AA which 
spans CR3 (144-191); and 187-289AA which spans CR4 (240-288AA). 
Immunoprecipitation of STING was followed by western blotting with polyclonal anti-
GFP antibody (Figure 3.2B). Consistent with Figure 3.1B, STING-HA binds to the N-
terminal region of HAdV-5. However, this contradicts the notion that the LXCXE motif is 
necessary and sufficient for E1A-STING binding as the LXCXE motif is located within 
the CR2 region. 
3.1.3  Assessing the Interaction Between STING and the 
Extreme N-terminus Region of E1A 
To further analyze and map the region of HAdV-5 E1A required for interaction with 
STING, multiple E1A constructs were generated that spanned the N-terminus. E1A 
constructs consisted of amino acid residues 1-14AA, 14-22AA, 16-22AA, and 19-49AA.  
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Figure 3.2. STING binds to the HAdV-5 E1A N-terminus and CR1. (A) Diagram 
depicting the conserved amino acid regions (CRs) of human adenovirus E1A. (B) 
HT1080 cells were transfected with 5 µg of human STING-HA expression vector and 
5 µg of either N terminus-GFP, CR2-GFP, CR3-GFP, or C terminus-GFP E1A 
expression vector. After 24 hr, cells were harvested and lysed, followed by 
immunoprecipitation of STING and western blotting for GFP-tagged E1A proteins. 
GFP was used as a control with STING-HA. IgG HC denotes the heavy chain. Inputs 
shown in the bottom panel. Results representative of three independent experiments. 
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Co-immunoprecipitation experiments were conducted in HT1080 cells using anti-STING 
antibody, followed by western blotting with anti- GFP antibody. The first 14 amino acid 
residues of E1A were found to bind STING, while E1A amino acid residues 29-49 were 
found to mediate a much weaker binding, as indicated by a faint signal (Figure 3.3A). 
However, this 29-49AA mutant was present at a much higher concentration within the 
lysate (as shown by the input), potentially producing a false-positive result. This finding 
was consistent with earlier results indicating that the N-terminus was an important region 
of interaction between E1A and STING. 
To further verify that the region of HAdV-5 E1A was required for binding STING in vitro, 
deletion mutants were prepared by removing stretches of amino acids within the N-terminal 
backbone (Figure 3.3B). These small deletion mutants of E1A are well characterized and 
the biological effects of these mutations have been studied in different models (Jelsma et 
al., 1988). The dl1101 mutant contains deletion of amino acid residues 4-25, the dl1102 
mutant contains deletion of amino acid residues 26-35, and the dl1103 mutant contains the 
deletion of amino acid residues 30-49. As Figure 3.3C indicates, the WT N-terminus and 
dl1103 E1A mutants were found to bind STING, while dl1101 and dl1102 had significantly 
reduced/non-detectable binding. This is consistent with the previous finding that the first 
14 amino acid residues were of particular importance for interaction. This also supports 
the hypothesis that the LXCXE motif is not sufficient for interaction. As the dl1103 mutant 
was also found to bind STING, it supports the earlier suggestion that the N-terminal amino 
acid residues 29-49 do not play significant roles in mediating the interaction. 
3.1.4  The HAdV-5 LXCXE Motif is Not Necessary for Binding 
STING 
The suggestion by Lau et al. (2015) that the LXCXE motif was the point of interaction 
between HAdV-5 E1A and STING in HEK293 cells requires further investigation. 
HEK293 cells were immortalized by HAdV-5 E1A, and therefore express the E1A protein 
(Thomas & Smart, 2005). Despite the presence of endogenous E1A, Lau and colleagues 
co-transfected HEK293 cells with STING and an E1A construct containing mutations that 
disabled the LXCXE motif. They reported that these mutations within the LXCXE motif  
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Figure 3.3. STING binds the Extreme N-terminus of HAdV-5 E1A. (A) HT1080 
cells were transfected with 5 µg of human STING-HA expression vector and 5 µg of N 
terminus-GFP E1A expression vector mutants; 1-14AA, 14-22AA, 16-22AA, and 29-
49AA. After 24 hr, cells were harvested and lysed, followed by immunoprecipitation of 
STING and western blotting for GFP-tagged E1A mutants with anti-GFP antibody. GFP 
was used as a control with STING-HA. Inputs shown in the bottom panel. IgG HC 
denotes the heavy chain. (B) Diagram depicting the E1A N-terminus deletion mutants; 
dl1101 (∆4-25), dl1102 (∆26-35), dl1103 (∆30-49). (C) HT1080 cells were transfected 
with 5 µg of human STING-HA expression vector and 5 µg of N terminus-GFP and N-
terminus-GFP deletion mutants dl1101 (∆4-25), dl1102 (∆26-35) and dl1103 (∆30-49). 
IgG HC denotes the heavy chain. IgG LC denotes the light chain. Inputs shown in right 
panel. Results representative of three independent experiments. 
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abolished binding with STING, as compared to WT full length E1A. To verify and explore 
further, I co-transfected HEK293 cells with GFP-tagged HAdV-5 13S E1A and a GFP-
tagged dl1108 E1A construct. The dl1108 E1A mutant construct contains a deletion of 
amino acids 122-126, which removes the CXE of the LXCXE motif to effectively abolish 
the motif (Figure 3.4A). This mutant has previously been documented to be transformation 
defective and does not bind pRb or p130 (Egan et al., 1988; Jelsma et al., 1988). 
Immunoprecipitation with anti-STING was followed by western blotting for anti-GFP and 
anti-E1A (anti-M73 antibody)(Figure 3.4B). In agreement with Lau and colleagues, 
transfection and immunoprecipitation with anti-STING was found to be sufficient for 
binding between ectopically expressed STING and endogenous 13S, but contrary to their 
findings, the LXCXE mutant dl1108 was still capable of binding STING. There is a slight 
spillover in the empty lane because of partial well collapse.  
To further my analysis, I chose a different cellular model. HT1080 cells were prepared and 
a series of deletion mutants spanning the CR2 region of HAdV-5 (including the LXCXE 
motif), were constructed. Deletion mutant dl1107, which deletes amino acids 111-123, and 
dl1108, which deletes amino acids 124-127, both disrupt the LXCXE motif. Either of the 
two deletion mutants should theoretically inhibit binding with STING if the LXCXE motif 
is necessary for the interaction with STING. Additional deletion mutants were constructed 
that flanked both sides of the LXCXE motif, or removed part of CR1 (see Figure 3.4A). 
Immunoprecipitation with STING was followed by western blotting with anti-GFP. As 
shown in figure 3.4C, all of the deletion mutants displayed binding affinity with STING. 
There was a noticeable reduction in expression between dl1107 and dl1108 with STING, 
which could potentially indicate that the LXCXE motif may play a secondary role in the 
interaction with STING. 
3.1.5  Analysis of the Conserved Interaction Between STING 
and 13S E1A from Representative Members of HAdV Species 
A to G 
Across the various distinct species and serotypes of Adenovirus, there are multiple  
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Figure 3.4. STING binds E1A LXCXE deletion mutants. (A) Diagram depicting 
characterized E1A deletion mutants that span CR1, CR2 and the region preceding CR2. 
The red box indicates the LXCXE motif. Deletion mutants dl1107 and dl1108 disable 
the LXCXE motif. (B) HEK293 cells were transfected with 5 µg of STING-HA and 5 
µg of E1A-GFP deletion mutant dl1108. After 24 hr, cell were harvested and lysed, 
followed by immunoprecipitation of STING and western blotting for E1A or GFP-
tagged protein using anti-E1A (anti-M73) and anti-GFP antibodies. 13S E1A at 40kDa 
represents endogenous E1A. Inputs shown in the right panel.  (C)  HT1080 cells were 
transfected with 5 µg of human STING-HA expression vector and 5 µg of E1A-GFP 
deletion mutants; dl1105, dl1106, dll107, dl1108, and dl1109.After 24 hr, cells were 
harvested and lysed, followed by immunoprecipitation of STING and western blotting 
for GFP-tagged E1A mutants with anti-GFP antibody. Inputs shown in right panel. IgG 
HC denotes the heavy chain. Results representative of two (B) or three independent 
experiments (C). 
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conserved motifs that interact with important cellular proteins such as GCN5, CtBP, p300 
and pRb (Avvakumov et al., 2004; Pelka et al., 2008). The identification of new proteins 
that demonstrate conserved interactions with multiple species of E1A may indicate new 
important roles for those proteins during the Adenoviral lifecycle. To determine if STING 
could bind multiple species of Adenoviral E1A protein, we utilized a series of 13S E1A 
constructs representing the major species groups of Adenovirus A through G (Figure 3.5A). 
The constructs represented were HAdV-3,-4,-5,-9,-12,-40, and-52. 13S E1A constructs 
were co-transfected with STING into HT1080 cells and immunoprecipitation with STING 
was followed by western blotting with anti-GFP. The binding between HAdV-52 and 
STING was almost non-detectable (Figure 3.5B), but an interaction was detected for all 
other serotypes.	
	
The next investigation was to look at the extreme N-terminus of each species as shown in 
Figure 3.6A. There is a considerable level of conservation between species within this 
region of the N-terminus. Each GFP-tagged E1A mutant construct was co-transfected with 
STING into HT1080 cells and immunoprecipitation with STING was followed by western 
blotting with anti-GFP. As demonstrated in Figure 3.6B, the N-terminus 1-15AA mutants 
of HAdV-5,-3,-9,-12, and -40 interacted with STING, whilst HAdV-52 did not.  
	
3.2   Assessment of the Interaction Between E1A, S6K and 
RPS6 
Wang and colleagues (2016) demonstrated a novel interaction between mouse p70 S6K1 
and mouse STING. The p70 S6 kinase is a mitogen activated serine/threonine kinase 
necessary for cell growth and survival. Studies have demonstrated that S6K regulates 
protein synthesis (Thomas, 2000), cell cycle progression (Lane et al., 1993), and cell size 
(Montagne et al., 1999). Through an in vitro model of chronic activation of the cGAS-
STING pathway via transduction of cells with recombinant virus, Wang and colleagues 
showed that S6K1 associates with the STING-TBK1 IRF3 complex, leading to IRF3 
phosphorylation and translocation to the nucleus. Disruption of this S6K1-STING 
interaction resulted in the abolition of IRF3 phosphorylation and translocation.  I posed the   
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Figure 3.5. Interaction between STING and E1A conserved across multiple 
species. (A) Diagram depicting the seven (A-G) HAdV species and respective 
serotypes. Serotypes highlighted in red were expressed at full length (13S) in GFP 
constructs. (B) HT1080 cells were co-transfected with 5 µg of human STING-HA 
expression vector and 5 µg of 13S E1A-GFP expression vectors representing the seven 
HAdV species; HAdV-3,-4,-5,-9,-12,-40, and -52. After 24 hr, cells were harvested and 
lysed, followed by immunoprecipitation of STING and western blotting for GFP-tagged 
13S E1A serotypes with anti-GFP antibody. Inputs shown in bottom panel. IgG HC 
denotes the heavy chain, IgG LC denotes the light chain. Results representative of three 
independent experiments. 
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Figure 3.6. E1A extreme N-terminus interaction with STING conservation across 
multiple species. (A) Diagram depicting the sequence alignment of amino acids 1-80 
across multiple serotypes representing homology across seven HAdV species. Shaded 
areas represent conservation in sequence across serotypes. (B) HT1080 cells were 
transfected with 5 µg of human STING-HA expression vector and 5 µg of 13S E1A-
GFP expression vectors representing amino acids 1-14 across seven HAdV species; 
HAdV-3,-4,-5,-9,-12,-40, and -52. After 24 hr, cells were harvested and lysed, followed 
by immunoprecipitation of STING and western blotting for GFP-tagged E1A serotypes 
with anti-GFP antibody. Inputs shown in right panel. IgG HC denotes the heavy chain. 
Results representative of three independent experiments. 
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question as to whether E1A was involved in this S6K1-STING-TBK1-IRF3 complex. To 
date, there has been only one report published investigating induction of p70 S6K by 
Adenovirus E1A (de Groot et al, 1995). This study reported that the induction was not 
mediated through protein-protein interactions, but this cannot be verified as the relevant 
data was not published. I sought to revisit this connection between E1A and S6K, with the 
aim of demonstrating that E1A can indeed, bind S6K1. Finding ancillary binding partners 
of E1A that also bind STING, TBK1 and IRF3 could further help to investigate the nature 
of the E1A-STING interaction. Ancillary binding partners of E1A could bridge the 
interaction with STING. In addition to S6K1, there are no existing reports analyzing the 
molecular relationship between E1A and ribosomal protein S6 (RPS6). The RPS6 operates 
within the mTORC1 signaling pathway to promote protein synthesis and is the most 
extensively studied S6K substrate. Nevertheless, the biochemical consequences of RPS6 
phosphorylation by S6K have yet to be fully determined (Meyuhas, 2008; Meyuhas & 
Dreazen, 2009). Wang and colleagues (2016) did not investigate whether RPS6 was 
involved in the S6K1-STING-TBK1-IRF3 complex. Therefore, to extend my exploration 
of this topic, I also sought to determine if E1A could interact with RPS6. A novel 
interaction between E1A and RPS6 would also facilitate future exploration into how E1A 
could potentially modulate known proteins involved in metabolic and innate immune 
pathways to create a more conducive environment for viral infection.	
3.2.1 Verifying the Interaction Between S6K and STING	
To expand on Wang and colleagues (2016) finding that S6K binds STING, I assessed if 
this interaction existed in HEK293 cells. I co-transfected a human STING-HA expression 
construct with a mouse S6K1-HA expression construct kindly gifted by Wang and 
colleagues (McMaster University). Co-immunoprecipitations were undertaken using either 
anti-STING or anti-E1A (anti-M73 + anti-M58) antibodies, followed by western blotting 
with anti-STING, anti-S6K, and anti-E1A antibodies. As shown in Figure 3.7A, 
immunoprecipitation with STING verified that mouse S6K binds to human STING. An 
interaction between S6K and STING was observed, and STING also immunoprecipitated 
endogenous E1A. The question of whether these three proteins are in complex cannot be 
determined from this experiment. Interestingly, immunoprecipitation with E1A   
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Figure 3.7. HAdV-5 E1A interacts with mouse S6K1. (A) HEK293 cells were 
transfected with 5 µg of human STING-HA expression vector and 5 µg of mouse S6K1-
HA expression vector. After 24 hr, cells were harvested and lysed, followed by 
immunoprecipitation of STING and western blotting for endogenous E1A, S6K1-HA, 
and STING-HA. Inputs shown in right panel. IgG HC denotes the heavy chain. (B) 
HEK293 cells were transfected with 5 µg of human STING-HA expression vector and 
5 µg of mouse S6K1-HA expression vector. After 24 hr, cells were harvested and lysed, 
followed by immunoprecipitation of endogenous E1A and western blotting for E1A, 
S6K1-HA, and STING-HA. Inputs shown in right panel. IgG HC denotes the heavy 
chain. Results representative of two independent experiments. 
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(Figure 3.7B) indicated that endogenous E1A was able to co-immunoprecipitate with 
exogenous mouse S6K1, and produce a strong signal. On the contrary, endogenous E1A 
did not co-immunoprecipitate with exogenous STING. It is to be assumed that E1A and 
STING will bind endogenous S6K within the system, but overexpression of mouse S6K1 
aids in studying these interactions. When comparing the input signals between STING and 
S6K1, the inability of endogenous E1A to bind STING through immunoprecipitation with 
E1A was unexpected.  	
	
3.2.2 E1A Binds Endogenous S6K and RPS6	
The first indications that E1A could potentially bind human S6K and RPS6 came from co-
immunoprecipitation studies in HEK293 cells, which endogenously express HAdV-5 E1A. 
13S E1A constructs in pcDNA3.1 were co-transfected with STING-HA or pcDNA3.1 
vector. As shown in Figure 3.8, immunoprecipitation with E1A (anti-M73), followed by 
western blotting for STING-HA, E1A, endogenous S6K, and endogenous RPS6. 13S E1A 
alone, was found to co-immunoprecipitate with both endogenous S6K and RPS6. The p70 
S6K signal was very strong, while the p85 S6K signal was much weaker. The presence of 
STING did not appear to be a requirement for co-immunoprecipitation of S6K and RPS6 
with 13S HAdV-5 E1A. In support of previous results (Figure 3.7), the endogenous E1A 
present in the control did not co-immunoprecipitate well with STING-HA. In addition, 
overexpression of 13S E1A was required to co-immunoprecipitate E1A with RPS6. 
However, a strong p70 S6K signal was detected with E1A in the control co-
immunoprecipitation, but not p85 S6K. If E1A does not require STING to bind S6K, then 
S6K may act as a bridge between E1A and STING. 
3.2.3 Characterizing the Interaction Between Mouse S6K1 
and HAdV E1A 
To verify the interaction of HAdV with mouse S6K1, we overexpressed these proteins with 
epitope tags in HT1080 cells for co-immunoprecipitation studies. We used mouse S6K1 
because it was kindly gifted by Wang and colleagues and has 99% sequence homology to  
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Figure 3.8. HAdV-5 E1A binds endogenous human S6K and RPS6. HEK293 cells 
were transfected with 5 µg of human STING-HA expression vector and 5 µg of 13S 
E1A-pcDNA3.1 expression vector (no tag). After 24 hr, cells were harvested and lysed, 
followed by immunoprecipitation of STING and western blotting for endogenous E1A, 
endogenous S6K, and endogenous RPS6. Inputs shown in right panel. Results 
representative of two independent experiments. 
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Figure 3.9. HAdV-5 interaction with mouse S6K1 conserved across serotypes. 
HT1080 cells were transfected with 5 µg of HAdV 13S-GFP expression vectors 
representing HAdV-3,-4,-5,-9,-40-and -52, and 5 µg of mouse S6K1-HA expression 
vector. After 24 hr, cells were harvested and lysed, followed by immunoprecipitation 
of S6K and western blotting for E1A-GFP. Inputs shown in right panel. IgG HC denotes 
the heavy chain. Results representative of three independent experiments. 
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human S6K1. To assess the conservation of this reaction, GFP-tagged 13S E1A serotypes 
representing the major Adenoviral families were co-immunoprecipitated with HA-tagged 
S6K1 using anti-S6K1 antibody. As shown in Figure 3.9, western blotting was undertaken 
with anti-GFP antibody and the results indicate that HAdV-5,-3,-4,-9, and -12, have 
relatively strong interactions with mouse S6K1, as compared to HAdV-40 and -52. This 
indicates that the interacting motif is fairly well conserved but not present within all E1A 
species. 
3.2.4 Assessing the Effect of Ectopically Expressed S6K2 on 
HAdV-5 E1A-S6K1 and HAdV-5 E1A-RPS6 Interaction 
The physiological and cellular roles of S6K1 are well documented (Magnuson et al., 2012), 
but less is known about S6K2. Over the past few years, researchers have demonstrated that 
S6K1 and S6K2 have high sequence homology, but S6K2 has additional cellular functions 
that are independent of S6K1 (Pardo & Seckl, 2013). The predominant form of S6K1, p70, 
is localized mainly to the cytoplasm, while the p85 isoform, which contains a nuclear 
localization sequence, is mainly found within the nucleus. S6K2 has two isoforms, a 
predominant p54 form and a p56 form. Both of these S6K2 isoforms contain nuclear 
localization signals and reside mainly in the nucleus of resting cells (Karlsson et al., 2015). 
Within human tissues, S6K2 is expressed at various levels, but expression levels are often 
inversely correlated with those of S6K1 (Nardella et al., 2011). I wanted to determine if 
overexpressing S6K2 protein in HT1080 cells effected protein expression levels of S6K1. 
I also wished to determine if overexpression of RPS6 effected the interaction between 
RPS6 and 13S E1A, and S6K1 and 13S E1A. 
A human S6K2 plasmid, and a human RPS6 plasmid, were constructed for co-transfection 
into HT1080 cells with 13S E1A. As shown in Figure 3.10, immunoprecipitation with E1A 
(anti-M73 antibody), was followed by western blotting with anti-S6K antibody and anti-
RPS6 antibody. The results suggest that S6K can bind RPS6 and co-immunoprecipitate 
with E1A. The limitation to this particular experiment was that the anti-S6K antibody used 
is specific for p70 and p85 S6K1, and not S6K2. Our previous results demonstrated that 
endogenous E1A in HEK293 cells could immunoprecipitate with endogenous p70 S6K1  
	 67	
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure 3.10. Overexpression of RPS6 and S6K2 are required for interaction 
between ectopically expressed HAdV-5 E1A and p70 S6K. HT1080 cells were 
transfected with 5 µg of HAdV-5 13S (no tag) expression vector and 5 µg of human 
S6K2 expression vector or 5 µg of human RPS6 expression vector. After 24 hr, cells 
were harvested and lysed, followed by immunoprecipitation of E1A and western 
blotting for S6K1 and RPS6. Inputs shown in right  panel. IgG HC denotes the heavy 
chain. Results representative of two independent experiments.  
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(Figure 3.8). However, in our HT1080 cellular model, transfected 13S E1A construct did 
not immunoprecipitate with endogenous p70 or p85 S6K1. On the contrary, co-transfection 
of either S6K2 or RPS6 with 13S E1A did result in the co-immunoprecipitation of p70/p85 
S6K1 with E1A. The overexpression of S6K2 and RPS6 would appear to enhance 
expression of S6K1.	
3.2.5 Assessing the Conserved Nature of the E1A and RPS6 
Interaction 
Since the novel interaction between RPS6 and HAdV-5 E1A was established in my earlier 
studies, I sought to evaluate if this interaction was conserved across multiple species of 
adenovirus. Immunoprecipitation experiments with RPS6, were followed by western 
blotting for GFP and RPS6. The adenovirus E1A species constructs were 13S GFP-tagged 
isoforms. As shown in Figure 3.11, HAdV-5 E1A was the only E1A species found to 
interact with RPS6. This verifies earlier E1A-RPS6 interaction experiments that used only 
the 13S HAdV-5 E1A isoform (Figure 3.10). This result indicates that HAdV-5 E1A is 
unique in its binding to RPS6, and that the E1A-RPS6 interaction is not conserved across 
all species of Adenovirus, potentially indicating that the interaction is not mediated through 
conserved linear motifs. 
Ribosomal proteins are not exclusively cytoplasmic, for example the the RPS6 protein has 
the ability to shuttle across the nuclear membrane and accumulate in the nucleus. To test 
whether RPS6 binds HAdV-5 in the presence of STING, and therefore potentially in the 
cytoplasm, we co- transfected 13S E1A-pcDNA, dl1106-pcDNA, and dl1108-pcDNA, with 
STING-HA into HT1080 cells. Immunoprecipitation with endogenous RPS6 was followed 
by western blotting for E1A and STING-HA (Figure 3.12). If endogenous RPS6 was able 
to bind overexpressed STING, then we expected to see a positive signal, but this was not 
observed. Endogenous RPS6 did however, bind overexpressed 13S E1A and dl1108 
deletion mutant, but there was no strong signal observed with dl1106 or dl1107 deletion 
mutants. The deletion mutant dl1107 and particularly dl1106 abolish stretches of amino 
acid residues that are not conserved across all HAdV species and are unique to HAdV-5, 
whereas the dl1108 deletion mutant abolishes a conserved amino acid region. 
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Figure 3.11. E1A interaction with RPS6 is unique for HAdV-5 serotype. HT1080 
cells were transfected with 5 µg of HAdV 13S-GFP expression vectors representing 
HAdV-3,-4,-5,-9,-40-and -52, and 5 µg of RPS6 expression vector. After 24 hr, cells 
were harvested and lysed, followed by immunoprecipitation of RPS6 and western 
blotting for E1A-GFP. Inputs shown in right panel. IgG HC denotes the heavy chain. 
Results representative of two independent experiments.   
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Figure 3.12. HAdV-5 E1A deletion mutants adjacent to or located at the N-
terminus of CR2 abolish binding with RPS6.	HT0180 cells were transfected with 5 
µg of HAdV-5 13S or deletion mutant expression vectors dl1106, dl1007, and dl1108 
(no tag), and 5 µg of STING-HA expression vector. After 24 hr, cells were harvested 
and lysed, followed by immunoprecipitation of RPS6 and western blotting for E1A 
(anti-M73) and STING-HA. Inputs shown in right panel. Results representative of two 
independent experiments.   
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Chapter 4 
Discussion 
4.1     Mapping the interaction between E1A and STING 
 
The ability to evade type I IFN responses is a fundamental aspect of the viral lifecycle. 
Viruses employ numerous strategies to conceal their presence and disable cellular innate 
defences. As discussed in the introduction, previous studies have described how human 
Adenovirus can modulate secondary type I IFN responses, but evasion of the primary type 
I IFN response is less well understood. The group of Stetson (Lau et al., 2015) discovered 
that HAdV-5 E1A could antagonize the cGAS-STING pathway in HEK293 cells, but the 
nature of the protein-protein interaction between HAdV-5 E1A and STING required further 
investigation.  
 
This study was based on the indication from the group of Stetson that HAdV-5 E1A 
interacts with STING through the LXCXE motif, and that this antagonism would 
theoretically prevent the phosphorylation of IRF3 and TBK1, subsequently disabling the 
release of type I IFN. The involvement of the zinc finger located in CR3 was also 
postulated, though without validation with data, as potentially being involved in the E1A-
STING interaction (Lau et al., 2015). These studies established parameters from which my 
own experiments initiated.  
 
My data, derived here from co-immunoprecipitation studies, does not support the concept 
that the LXCXE motif is both necessary and sufficient for binding to STING. As described 
in section 1.4, the cGAS-STING DNA sensing pathway has several distinct components, 
but many of these are in complex with each other. Previous studies have demonstrated that 
cGAS is not expressed in HEK293 cells, therefore, STING is assumed to be the DNA 
sensor in that pathway. The latest communication from the group of Stetson indicated that 
the early events of this pathway were intact, suggesting that STING traffics from the 
endoplasmic reticulum and recruits TBK1. Phosphorylation of IRF3 on serine 386 was 
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intact, while phosphorylation of serine 396 was impaired (Burleigh & Stetson, 2016). This 
suggests that E1A was targeting a later step in the pathway and binds STING in complex 
with other proteins. Indeed, the E1A-STING interaction may not be a direct protein-protein 
interaction.  Wang et al. (2016) found that co-transfection of a plasmid encoding STING 
together with a plasmid encoding S6K1 augmented the STING-dependent phosphorylation 
of serine 396 of endogenous IRF3 in HEK293T cells. I demonstrated that HAdV-5 E1A 
binds STING, but we cannot rule out the possibility that HAdV-5 E1A binds STING 
through S6K1, or binds a surface created by the complex of these two proteins.  
 
I began this study with the expectation that STING would bind HAdV-5 E1A through the 
LXCXE motif, much in the same way that E1A binds pRb through the LXCXE motif. 
Previous members of the laboratory have shown that an E1A CR2 deletion mutant, which 
encodes the LXCXE sequence, can readily co-immunoprecipitate with pRb following co-
transfection experiments (unpublished data). I expected to observe a strong interaction 
between STING and CR2 using co-immunoprecipitation experiments, but this was not 
seen. Through my own studies, I also could not confirm Stetson’s finding that an LXCXE 
mutant abolished E1A binding with STING in HEK293 cells. When I expanded across an 
atlas of mutations spanning the CR2 region and conducted my experiments in HT1080 
cells, I observed binding between STING and E1A was only slightly diminished. These 
results indicated that other regions of E1A were likely involved in mediating the interaction 
with STING. 
 
The N-terminal region of E1A, covering amino acid residues 1-82, consistently bound to 
STING despite lower overall expression levels in the input cell lysate. Further analysis of 
the N-terminus led me to construct expression plasmids containing various portions of the 
E1A N-terminal sequence. Co-immunoprecipitation experiments demonstrated that the 
first fourteen residues of HAdV-5 E1A were mediating an interaction with STING.  
 
The conserved regions of E1A are largely considered to be disordered, predicted using the 
online tool PONDR (predictor of natural disordered regions)(Pelka et al., 2013). E1A is 
well characterized for its ability to interact with proteins through short linear interaction 
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motifs (Pelka et al., 2013). Linear motifs are also regarded as ‘evolutionary switches’ 
because subtle amino acid changes can cause short sequences in linear motifs to appear 
and disappear (Neduva & Russell, 2005). The short lengths of these motifs typically mean 
that the interactions they mediate are transient and of low affinity. In order to verify that 
the interaction between STING and the first 14 amino acid residues of E1A are not a 
laboratory artifact of protein fragmentation, deletion mutants were prepared within the N-
terminus that eliminated these amino acid residues. This approach complements earlier 
experiments because the deletion mutants would not bind STING if the 14 amino acid 
residues were critical for the interaction. The binding between STING and the E1A N-
terminus was greatly diminished in E1A deletion mutants lacking amino acids residues 4 
to 25. Thus, the N-terminus of E1A appears necessary and sufficient for mediating the 
interaction with STING. 
 
Determining the conservation of the interaction between STING and 13S E1A could 
provide insight into the importance of the interaction from an evolutionary perspective. I 
demonstrated that the interaction between E1A and STING was fairly conserved across 
most species of E1A representing the major families of Adenovirus. The conservation of 
interaction also indicated that conserved motifs within these species may be facilitating the 
E1A and STING interaction. To further investigate the N-terminal region, I prepared N-
terminal constructs spanning the first 15 amino acid residues of various E1A species. I 
observed that the N-terminus (1-15AA) of HAdV-3,-9,-12, and -40 interacted with STING, 
while HAdV-52 and 13S ∆N-terminus (∆1-80) did not. This suggests that the N-terminus 
(1-15AA) interaction with STING is likely significant and fundamental across most 
Adenoviral species for type I IFN evasion strategies. HAdV-52, which did not bind STING, 
contains considerable differences in the amino acid residues of the extreme N-terminus as 
compared to other Adenoviral species. Indeed, HAdV-52 is the most divergent species 
(refer to Figure 1.5). Interestingly, an interaction was detected between STING and the 
HAdV-9 N-terminus. Beyond the first 8 amino acids, the HAdV-9 N-terminus is divergent 
from the other representative serotypes, which would indicate that further exploration of 
the extreme N-terminus, namely amino acids 1-8, should continue.  
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Past studies have demonstrated that the E1A N-terminus can interact with multiple proteins 
including the TATA binding domain (TBP), p300 and CREB-binding domain (CBP) 
(Boyd et al., 2002). Mutation of cysteine at position 6 to alanine abolished the E1A 
interaction with TBP, p300 and CBP. Following infection, the phosphorylation of IRF3 
results in the dimerization and translocation to the nucleus. Upon accumulating in the 
nucleus, IRF3 binds with CBP and p300. The binding of E1A to p300/CBP through the N-
terminus prevents this interaction between IRF3 and CBP/p300, resulting in an inhibition 
of type I IFN production (Wathelet et al., 1998; Yang et al., 2002, 2004; Yoneyama et al., 
1998). Despite reports that p300 can be found in the cytoplasm, the prevailing notion is 
that the nuclear expression of p300 is predominant (Rotte et al., 2013). This suggests there 
is a novel binding region within the N-terminus that either binds STING within the 
cytoplasm, or a protein in complex with STING. As STING is not known to accumulate in 
the nucleus, future work should remain focused on the discovery of E1A cytoplasmic 
binding partners.  
4.2     Characterizing the interaction between E1A, S6K1 and 
RPS6 
Wang and colleagues (2016) revealed that S6K1 played a new role in the induction of type 
I IFN responses. Our second aim of this study was to determine whether E1A was involved 
in the STING-S6K1 interaction, and whether the ribosomal protein S6, which is 
downstream of S6K1, could also be potentially involved.   
 
A study by de Groot et al. (1995) reported that the HAdV-5 N-terminus (possibly including 
CR1) was responsible for enhancing expression of p70 S6K. However, they stated (without 
supporting data) that there was no protein-protein interaction. I revisited this question and 
showed that E1A can bind both endogenous and exogenous mouse and human p70 S6K 
through co-immunoprecipitation studies.  I used a mouse S6K1 construct because it was 
donated by Wang and colleagues (McMaster University) and has 99% amino acid sequence 
homology to human S6K1. I made the novel finding that binding of 13S E1A to p70 S6K1 
is fairly conserved across multiple E1A species. I also extended the study of Wang et al. 
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(2016) by demonstrating that human STING could immunoprecipitate with mouse p70 
S6K1. The precise binding configuration between p70 S6K1, E1A and STING has yet to 
be determined, and should be a priority for future investigation. Since E1A binds p70 S6K1 
in the absence of STING, it could be postulated that E1A binds p70 S6K1 through a 
conserved region, and p70 S6K in turn, binds STING. However, we cannot dismiss the 
possibility that these are separate events and E1A binds p70 S6K1 irrespective of any type 
I IFN evasion strategies.  
 
Changes in protein expression level of p85 S6K in response to E1A is unclear and further 
studies should be conducted to determine if E1A may somehow discriminate between the 
p70 S6K isoform and the p85 S6K isoform. The p85 S6K isoform is less abundant than 
p70 S6K in most cell types (Reinhard et al., 1992), which explains why we observe stronger 
interactions between E1A and p70 S6K. The p70 S6K isoform was observed to 
immunoprecipitate with endogenous E1A in HEK293 cells, whereas the p85 isoform did 
not. Overexpression of the E1A protein is required to immunoprecipitate p85 S6K1 with 
E1A. However, like p70 S6K, p85 S6K does not require the presence of STING to bind 
E1A. 
 
Understanding the biological functions of S6K2 has been largely neglected compared to 
the number of studies investigating S6K1. In addition, the changes in S6K2 expression 
upon viral infection is largely undetermined. It would be interesting to determine if HAdV 
E1A interacts with S6K2, and if HAdV infection alters the protein expression of S6K2. 
 
Indications that E1A could bind RPS6 initially came from positive endogenous RPS6 
signals found in co-immunoprecipitation experiments transfecting 13S E1A into HEK293 
cells. When I co-transfected RPS6 with multiple HAdV species in HT1080 cells, I initially 
encountered problems in detecting a signal. However, by increasing the expression of the 
exogenous RPS6 protein I was able to determine that RPS6 binds HAdV-5, but not the 
other E1A species. The result demonstrating that dl1106 failed to bind RPS6 may suggest 
that E1A HAdV-5 has a unique binding region. The absence of RPS6 binding to STING 
could be due to the fact that STING resides in the cytoplasm, while RPS6 can be found in 
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the nucleus. E1A primarily localizes to the nucleus (Jiang et al., 2006) and this may be the 
site of interaction with RPS6, however, E1A may also redistribute RPS6 proteins 
intracellularly. 
4.3     Significance of Findings and Future Directions  
My studies have shown that amino acid residues 1-14 of the E1A N-terminus are 
responsible for mediating the interaction between E1A and STING, and that this interaction 
is quite conserved across Adenoviral species. This demonstrates a novel binding site within 
the N-terminus region of E1A, distinct from the putative interaction via the LXCXE motif 
in CR2. We have also discovered novel E1A binding partners; p70 S6K1, p85 S6K1, and 
RPS6. The interaction between E1A and S6K1 is fairly conserved, indicating that a 
conserved motif is likely involved in mediating this interaction, either independently or in 
conjunction with additional binding sites. The novel interaction between HAdV-5 E1A and 
RPS6 is not conserved across adenoviral species and does not involve the STING complex. 
To verify the RPS6-E1A interaction, other serotypes of Adenovirus species C should also 
be tested for their ability to bind RPS6. Determining the functional significance of this 
interaction would expand our knowledge of E1A’s ability to modulate proteins involved in 
metabolic pathways. This study provides the first indication that E1A can target a 
downstream component of the mTOR pathway. The functional significance of the E1A-
S6K1 interaction also needs to be fully elucidated. E1A may modulate S6K for several 
purposes, and may act as both an enhancer and repressor of activity. Enhancing the role of 
S6K in protein synthesis could provide an environment more conducive to viral replication, 
whereas repressing an S6K-STING interaction blocks the type I IFN response.  
 
A catalogue of point mutations within the N-terminus region of E1A needs to be 
constructed to further identify the residues critical for interaction with STING. The region 
of S6K1 binding on E1A also needs to be mapped, providing specific reagents for future 
studies that will identify the exact impact of this interaction on the virus replicative cycle. 
To determine if E1A binds STING through S6K1 or co-binds both proteins, gene 
knockdown studies could be undertaken whereby E1A and STING are co-transfected into 
S6K1-/- cells followed by co-immunoprecipitation for STING. As S6K1 was shown by 
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Wang et al. (2016) to augment the STING-dependent phosphorylation of IRF3, 
theoretically, S6K1 would be an ideal target for E1A to disable the type I IFN response.  
Further investigation is required to verify the location of the E1A-S6K1 interaction, and 
the E1A-RPS6 interaction. Immunohistochemical staining of endogenous E1A in HEK293 
cells, or transfection of epitope-tagged constructs of E1A, S6K1, STING and RPS6 into 
HT1080 cells followed by immunofluorescence to track their localization within the cell 
could be utilized. The ability of E1A to relocalize components of the STING pathway 
should also be examined.  
 
To complement our previous results, a primary cell line such as mouse embryonic 
fibroblasts could be transduced with retroviruses encoding mutant E1A with mutations that 
disrupt binding with S6K. Changes in IFN-β mRNA levels upon stimulation with foreign 
dsDNA could be evaluated with qPCR. If disruption of  binding between E1A and S6K 
results in rescue of the type I IFN response, then an increase in IFN-β mRNA should be 
observed.  In addition, a screen could be developed in STING and cGAS knockdown cells 
to verify regions of  E1A that block IFN-β. Co-transfection of STING, cGAS, and mutant 
E1A expression plasmids, together with an IFN-β promoter luciferase reporter construct 
can identify which mutations rescue IFN-β activation (Ma et al., 2015). To complement 
our study with an infection model, viruses with deletion mutants in E1A rendering them 
unable to antagonize the STING-pathway should be constructed and tested in primary cell 
lines or the HEK293 cell line treated with CRISPR targeting deletion of the E1A loci.  
 
Lau et al. identified the Human Papilloma Virus (HPV) E7 protein as an antagonist of the 
STING pathway because it has an LXCXE motif. However, the HPV E7 protein does not 
have sequence homology to the HAdV N-terminus region discovered to interact with 
STING. Therefore, it would be of interest to determine if the E7 LXCXE motif, or a motif 
that overlaps the LXCXE motif may be inhibiting the phosphorylation of IRF3 at serine 
396.  I suggest this because the LXCXE motif HPV E7 protein was found to be involved 
in binding the carboxyl-terminal transactivation domain of IRF1 (Park et al., 2000). 
Additionally, a PEST domain that overlaps the LXCXE motif in the HPV 16 E7 protein 
has been found to interact with IRF9 (Antonsson et al., 2006). I would test to see if the 
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E1A LXCXE motif was involved in abolishing the phosphorylation of IRF3 at serine 396. 
E1A could be binding STING or S6K1 through the N-terminus and the LXCXE motif may 
be blocking IRF3 phosphorylation.    
 
I wish to point out the drawbacks of the HEK293 cell model with respect to experiments 
analyzing the STING-pathway. Many studies analyzing innate immune signaling have 
been completed in HEK293 cells. In addition to the absence of cGAS, a study published in 
August 2017 by Wu et al. revealed that STING does not undergo the same degradation 
processes in HEK293 cells as it does in human diploid cells. These processes are vital 
regulatory mechanisms used to avoid an excessive innate immune response. In human 
diploid cells, they reported that after stimulation by dsDNA, RIG-1 was found downstream 
of STING and operated with IL-6 and ULK1 through a negative feedback loop to activate 
and control STING degradation. Low levels of RIG-1 and IL-6 in HEK293 cells were 
found to be insufficient for ULK1 activation, resulting in the loss of STING degradation 
mechanisms (Wu et al., 2017). This leads to the question of whether HEK293 cells are a 
reliable model to study innate immune responses. HEK293 cells are generated through the 
transformation of normal HEK cells with sheared HAdV-5 E1A DNA. HEK293 cells have 
significantly less number of chromosomes than normal human diploid cells and are capable 
of infinite expansion. It was historically known that stimulation by dsDNA did not produce 
a type I IFN response in HEK293 cells (Lau et al., 2015). If E1A in HEK293 cells 
permanently antagonizes the STING-S6K1-TBK1-IRF3 complex, then through the process 
of passaging, HEK293 cells may no longer require the need for STING regulation. HeLa 
cells should also be investigated for presence of STING degradation pathways. In addition, 
future studies investigating viral modulation of metabolic pathways should be cautious 
about the enhanced expression levels of S6K in HEK293 cells, especially if S6K is used as 
a marker for protein synthesis.  
 
The present study has added new understanding to the intracellular interactors of E1A, and 
opened new avenues of research. Substantial studies remain to confirm the functional role 
of the protein-protein interactions identified.  
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